bexarotene has been researched along with Angiogenesis, Pathologic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Cheng, F; Li, G; Shen, D; Wu, Y; Xia, L; Yu, X | 1 |
| Escudero, P; Ferrando, C; Furio, E; Gonzalez-Navarro, H; Juez, M; Navarro, A; Piqueras, L; Sanz, MJ | 1 |
| Chen, G; Chen, K; Fu, S; Jia, L; Jiang, X; Li, H; Li, Y; Liu, X; Ren, Y; Wang, L; Wang, S; Wu, C; Yang, J | 1 |
| Lamph, WW; Yen, WC | 1 |
| Corpuz, MR; Lamph, WW; Negro-Vilar, A; Prudente, RY; Yen, WC | 1 |
| Chen, X; Ding, Y; Fu, J; Huang, D; Li, H | 1 |
1 review(s) available for bexarotene and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bexarotene; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplasms; Neovascularization, Pathologic | 2018 |
5 other study(ies) available for bexarotene and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Bexarotene; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Rosuvastatin Calcium; Signal Transduction; Tetrahydronaphthalenes | 2015 |
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
Topics: Aged; Animals; Antineoplastic Agents; Bexarotene; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase 1; Histones; HL-60 Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Retinoid X Receptor alpha; RNA, Small Interfering; Tetrahydronaphthalenes; Up-Regulation; Vascular Endothelial Growth Factor A | 2015 |
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Umbilical Veins | 2005 |
A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cell Line, Tumor; Cell Movement; Endothelial Cells; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Retinoid X Receptors; Tetrahydronaphthalenes; Transplantation, Heterologous; Umbilical Cord | 2006 |
The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrahydronaphthalenes; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |